



## Engineering a favourable osteogenic microenvironment by heparin mediated hybrid coating assembly and rhBMP-2 loading†

Haoqi Tan,<sup>ab</sup> Honglei Wang,<sup>ab</sup> Yanjun Chai,<sup>ab</sup> Yuanman Yu,<sup>ab</sup> Hua Hong,<sup>ab</sup> Fei Yang,<sup>c</sup> Xue Qu<sup>\*ab</sup> and Changsheng Liu<sup>\*ab</sup>

With the development of bone tissue engineering, it is a great challenge to fabricate a bioactive surface which can provide a favourable microenvironment for cell adhesion, migration and osteo-differentiation. Coating the as-prepared substrates with bioactive components is an effective method to induce osteogenesis. In this study, we designed a multi-layered hybrid coating containing hydroxyapatite nanoparticles, heparin and chitosan. Heparin is used to mediate the electrostatic assembly of hydroxyapatite nanoparticles with chitosan, as well as the subsequent recombinant human bone morphogenetic protein-2 (rhBMP-2) loading. Several independent pieces of evidence were provided to indicate the successful fabrication of the hybrid coating. Sustained release of rhBMP-2 by this coating was also achieved. The *in vitro* biological studies reveal that the hybrid coating system has excellent biocompatibility and can improve the osteo-differentiation especially for rhBMP-2 present on the coating surface. The results demonstrate that the proposed rhBMP-2 loaded hybrid coating can provide a favourable osteogenic microenvironment and has the potential to improve *in situ* bone repair due to its superior osteoconductivity as well as osteoinductivity.

Received 25th November 2016  
 Accepted 31st January 2017

DOI: 10.1039/c6ra27308d  
[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

### 1. Introduction

Bone defects and injuries caused by trauma or diseases represent major clinical problems.<sup>1–3</sup> Currently, implanting bone grafts for tissue engineering scaffolds has been widely used to address this issue.<sup>4,5</sup> The graft surface is the first contact with the organism and initiates subsequent biological responses. Therefore, engineering a favourable surface microenvironment for cell adhesion, migration and differentiation is critical for improving tissue repair and regeneration processes. In the case of bone regeneration, surface molecular engineering utilizes the specific molecules for instance collagen,<sup>6,7</sup> hydroxyapatite (HAp),<sup>8,9</sup> polysaccharide,<sup>10,11</sup> growthfactors<sup>12,13</sup> and bone therapeutic drugs<sup>14</sup> to conceive a favourable microenvironment to modulate implant–tissue interactions. HAp is a naturally occurring crystalline calcium phosphate  $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ . As one of the principal inorganic components of human hard tissues such as vertebrae and teeth, HAp has been proven to

offer better osteoconductivity,<sup>15,16</sup> leading to ultimate osteointegration when applied onto biomedical implant surfaces. Recombinant human bone morphogenetic protein-2 (rhBMP-2) is an important osteoinductive growth factor. rhBMP-2 is clinically used to treat persistent non-union, open tibial fractures and spine fusion because it can trigger bone generation by initiating the signal transduction pathway for osteo-differentiation inside cells.<sup>17,18</sup> Introducing both HAp and rhBMP-2 onto biomaterials surface is highly recommended to improve the microenvironment for osteogenesis related cells growth, and thus can achieve better osteogenesis and osteointegration.<sup>19</sup>

In this context, various strategies have been developed to modify the biomaterials' surface with HAp and rhBMP-2. Han *et al.* co-precipitated apatite crystals with BMP-2 nano-complex onto titanium surface *via* a simultaneous mineralization.<sup>20</sup> However, this process was time consuming, and also would lead to unanticipated protein denaturation. Tsai *et al.* developed a facile “one-pot” deposition method based on dopamine polymerization in the presence of HAp, rhBMP-2 and RGD conjugate, and thus can introduce these active components onto titanium quickly.<sup>21</sup> Although this method generated a cell-adhesive, osteoconductive, and osteoinductive implants surface, the dissolvable polydopamine coating would entrap these active components forever. The layer-by-layer (LbL) assembly of polyelectrolyte multilayered film represents an attractive approach to coat the substrate because of its

<sup>a</sup>Key Laboratory for Ultrafine Materials of Ministry of Education, East China University of Science and Technology, Shanghai 200237, China. E-mail: quxue@ecust.edu.cn; liucs@ecust.edu.cn; Fax: +86-21-64251358; Tel: +86-21-64251358

<sup>b</sup>The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China

<sup>c</sup>State Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ra27308d



simpleness of preparation, versatility in composition and substrates, and fine control over architecture.<sup>22–26</sup> Importantly, LbL film deposition does not require any organic media and therefore can incorporate sensitive biomacromolecules.<sup>27</sup> Recently, we have shown that well designed LbL coating assembled by polymer nanoparticles and polysaccharide can load and sustained release BMP-2 and dexamethasone, through which synergistic osteoinductivity was successfully achieved.<sup>28</sup>

In this study, we propose to assemble a hybrid LbL coating electrostatically to incorporate HAp and rhBMP-2 for bone regeneration. Here heparin is used to mediate the coating formation and rhBMP-2 loading. The strategy is illustrated in Scheme 1. (1) First HAp nanoparticles are conferred with negative charges by surface modification with heparin *via* dopamine chemistry. (2) And then heparinized HAp and polycation chitosan are assembled alternatively to form a hybrid coating in a LbL manner. (3) rhBMP-2 is finally introduced into this coating *via* the intermolecular binding with heparin, since heparin is known to interact with rhBMP-2 through sulfated group, thus can be used to load and stabilize rhBMP-2.<sup>29–32</sup> Planar PLGA polymers were used as a model substrate to build up this composite coating. The focus of our study is to demonstrate that the surface incorporation of HAp and rhBMP-2 can be easily achieved by utilizing the inherent characteristics of heparin (*i.e.* charge and sulfate unit). We envision this engineered surface structure can offer a good osteogenic microenvironment for bone development and regeneration.

Moreover, since layer-by-layer strategy is easy to be applied onto varying substrates, our proposed surface engineering strategy can be easily introduced onto varying biomedical implant surfaces to improve their osteogenetic performance.

## 2. Experimental

### 2.1 Materials


Poly(lactide-*co*-glycolide) (PLGA, LA : GA = 75 : 25,  $M_w$  = 100 kDa) was purchased from Jinan Daigang Biomaterial Co., Ltd. (Shandong, China). Hydroxyapatite nanoparticles (HApNPs) were synthesized in our researchgroup. rhBMP-2 was kindly supplied by Rebone Biomaterials Co., Ltd. (Shanghai, China). Chitosan (CS, medium molecular weight) and heparin (HEP) were purchased from Sigma-Aldrich (CA, USA). CCK-8 assay kit, BCA protein assay kit and rhBMP-2 ELISA assay kit were purchased from Beyotime Biotech (Jiangsu, China).

### 2.2 Synthesis of HEP-Dopa conjugate

HEP was grafted with dopamine (Dopa) using EDC and sulfo-NHS as coupling agents as presented in ESI.†

### 2.3 Heparin-modified hydroxyapatite nanoparticles

Ellipse-like shaped HApNPs (synthetic method was presented in ESI†) were dispersed in the Tris-HCl buffer (0.01 M pH = 8.0) at a concentration of 5 mg mL<sup>-1</sup>, followed by addition of



**Scheme 1** Heparin mediates the assembling of HAp nanoparticles and chitosan and subsequent rhBMP-2 loading for bone regeneration. (1) Heparin is modified onto HAp nanoparticles by dopamine chemistry to endow HAp with negative charges. (2) The hybrid coating is assembled in a layer-by-layer manner by using anionic HAp nanoparticles and cationic chitosan. (3) rhBMP-2 is post loaded into the coating *via* the interaction with heparin. This coating can provide good osteoconductivity and osteoinductivity for bone repair.

HEP-Dopa (2 mg mL<sup>-1</sup>). Ultrasonication was then applied to the prepared solution for 10 min using a Ultrasonic cleaner. After magnetic stirring at 60 °C for 12 h, the nanoparticles were collected by centrifugation, followed by rinsing with ultrapure water and centrifugation for 3 times to completely remove unbound HEP-Dopa molecules.

#### 2.4 Layer-by-layer assembly of multilayered coatings on PLGA substrate

PLGA film ( $M_w$  = 100 kDa, size 10 × 10 cm<sup>2</sup> with a thickness of 100 µm) was firstly cleaned by alcohol/water (1/1 v/v) solution for 30 min under ultrasonication, and dried under nitrogen. The PLGA film was subsequently immersed in PEI aqueous solution at a concentration of 10 mg mL<sup>-1</sup> for 1 h to obtain stable positively charged surface, then rinsed with ultrapure water.

The alternate assembly of HApNPs modified with HEP-Dopa (HEP-HApNPs) and chitosan (CS) was performed on the above film. Two solutions of HEP-HApNPs and CS were prepared by dispersion in HAc-NaAc buffer (0.2 M pH = 5) at a concentration of 5 mg mL<sup>-1</sup> and 2 mg mL<sup>-1</sup> respectively. For multilayer build-up, in brief, aminolysed PLGA film (denoted as bare substrate) was immersed in HEP-HApNPs suspension for 30 min under gentle agitating, then washed with ultrapure water and then dried under N<sub>2</sub> gas. Next, the substrate was immersed in CS solution for 30 min, followed by a washing and drying step. This alternate adsorption process was repeated to obtain the desired number of layers. The uppermost layer was always deposited with CS to confer biocompatibility.

#### 2.5 Characterization of HApNPs modified with HEP-Dopa and LBL multilayer coatings

Surface charge and hydrodynamic size of HEP-HApNPs were measured using a Zetasizer (Nano ZS, Malvern Instruments, UK). The dispersion stability of pure HApNPs, HApNPs/HEP mixture and HEP-HApNPs in PBS solution were recorded by camera. The morphology of the HApNPs and HEP-HApNPs were examined by transmission electron microscope (TEM, JEOL JEM-2100, Nikon, Japan) and field-emission scanning electron microscopy (FE-SEM, Hitachi S4800, Nikon, Japan). The amount of sulfo group in the surface of HApNPs was measured by barium chloride-gelatin turbidimetry.<sup>33</sup>

Quartz Crystal Microbalance with Dissipation Monitoring (QCM, Q-sense E1, Biolin, Sweden) was used to monitor the LBL self-assembly process. In brief, an aminolysed coating was firstly fabricated on the gold surface of the quartz crystal by PEI (4 mg mL<sup>-1</sup>) solution. Assembly of the multi-layer on the crystal was carried on by contacting HEP-HApNPs suspension (5 mg mL<sup>-1</sup>) and CS (2 mg mL<sup>-1</sup>) solution alternately at a flow rate of 50 µL min<sup>-1</sup>. To remove the loosely-bound molecules, buffer rinsing was employed for 5–10 min after the equilibrium state was reached for each absorption. Morphological characterization of top view and lateral view of the multilayered coatings were performed with SEM. In addition, to confirm the surface chemical composition, X-ray photoelectron spectroscopy (XPS, PH1500C, Japan) equipped with an argon ion gun was used.

#### 2.6 rhBMP-2 loading and release

rhBMP-2 was last loaded by dropping the solution containing 2 µg of rhBMP-2 onto the as-prepared coatings (1 cm<sup>2</sup>). Stand the films for 2 h to let rhBMP-2 absorbed fully before subsequent freeze-drying step. The control bare substrate (PLGA) containing the same amount of rhBMP-2 was prepared by the same operation method.

For evaluation of rhBMP-2 releasing profile, the bare substrate and substrate with LBL coatings loaded rhBMP-2 were placed into a tube containing 2 mL PBS respectively. At predetermined time of rhBMP-2 releasing profile, 0.3 mL incubation solution was collected from the tube for measurement and another 0.3 mL fresh PBS was supplemented. The amount of released rhBMP-2 was determined by using a Human rhBMP-2 ELISA Kit ( $n$  = 3).

#### 2.7 Cell evaluation

Murinemyoblast cells (C2C12) purchased from the American Type Culture Collection (ATCC, VA, USA) and rat bone marrow stromal cells (rBMSCs) extracted from rat bone marrow were used for evaluating osteogenesis vitality of the multilayer-coating. This study was performed in strict accordance with National Institutes of Health (NIH) guidelines for the care and use of laboratory animals (NIH Publication no. 85-23 Rev. 1985) and all procedures were approved by the Research Center for Laboratory Animals of Shanghai University of Traditional Chinese Medicine (Shanghai, China). The cell culture and cell implantation are presented in ESI.†

**2.7.1 Cell viability measurement.** The cell viability on the coating was evaluated by using a Cell Counting kit-8 (CCK-8). In brief, C2C12 cells were seeded on substrates (PLGA) with or without coating at a density of  $4 \times 10^4$  cells per film. After culturing for 3 days, 10% CCK-8 of medium was added per well and the plate was incubated at 37 °C for 4 h. Finally, the solution of each sample was added to 96-well plates in a separate volume of 200 µL. The plate was measured at 450 nm by an enzyme-linked immunosorbent assay plate reader (SPEC-TRAmax 384, Molecular Devices, USA) ( $n$  = 3).

**2.7.2 Cell morphological observation.** For cell morphology observation, a seeding density of  $4 \times 10^4$  C2C12 cells per film was applied. After 24 h incubation, cells were fixed with 2.5% glutaraldehyde solution for 15 min, and then cell were dehydrated using gradient ethanol–water solution step by step. After complete dry, the morphology of C2C12 cells on the multilayer film was observed by SEM. In addition, the fixed cells were attained with 5 µg mL<sup>-1</sup> of FITC-phalloidin for 15 min and 5 µg mL<sup>-1</sup> of DAPI for 15 min for cytoskeleton and nuclei staining respectively. Cells were observed by confocal laser scanning microscopy (CLSM, Nikon, Japan).

**2.7.3 Alkaline phosphatase (ALP) activity assay.** Cells were seeded on different interfaces (bare substrate, coating, coating loaded rhBMP-2) at a density of  $4 \times 10^4$  cells per film. After 3 days of incubation, the culture medium was removed and washed twice with PBS. Cells were lysed by adding 100 µL Nonidet P-40 (NP-40, 1%) solution per well for 90 min to obtain cell lysates. 50 µL of cell lysates from each sample was added to



96-well plates. Then 100  $\mu$ L of 2.5 mg mL<sup>-1</sup> *p*-nitrophenyl phosphate (*p*NPP) substrate solution composed of 1 mM MgCl<sub>2</sub>·6H<sub>2</sub>O and 0.1 M glycine was added and incubated for 45 min in refrigerator shaker (HZ-9610KB, UALIDA, China) at 37 °C. The reaction was quenched by adding 100  $\mu$ L of 0.1 M NaOH and the absorbance of the substrate solution at 405 nm was measured to determine the ALP activity by enzyme-linked immunoassay plate reader. Total protein content per well was determined using a BCA protein assay kit ( $n = 3$ ).

$$\text{ALP activity} = \text{absorbance of } 405 \text{ nm} / (\text{protein content} \times \text{color reaction time})$$

**2.7.4 Gene expression analysis.** RhBMSCs were seeded on different interfaces (bare substrate, coating, coating loaded rhBMP-2) in 24-well plates at a density of  $4 \times 10^4$  cells per film. After three days of cultivation, total RNA was extracted using Trizol reagent from cells. In brief, strand complementary DNA (cDNA) was synthesized from 2  $\mu$ g RNA using PrimeScript RT reagent Kit. RT-qPCR was performed in 20  $\mu$ L reaction volume containing 10  $\mu$ L SYBR Premix Ex TaqTM, 0.8  $\mu$ L (0.2  $\mu$ M) of each primer (forward and reverse), 1  $\mu$ L of cDNA, and 8.2 mL DEPC H<sub>2</sub>O. Realtime PCR was performed with a Bio-Rad Realtime PCR system (Bio-Rad, Hercules, CA, USA) on osteogenic differentiation markers of ALP, run-related transcription factor 2 (RunX2), osteocalcin (OCN), osteopontin (OPN) with glyceraldehydes-3-phosphatedehydrogenase (GAPDH) used as the house keeping gene. Cultures on the substrate without coating were set as blank control. Relative expression level for each gene (fold change) was calculated. Highly purified primer sequences used in this study were synthesized commercially (Shengong Co. Ltd. Shanghai, China) and listed in Table S1.† All experiments were performed in quintuplicate.

### 3. Results and discussion

#### 3.1 Fabrication of heparin-modified HAp nanoparticles

In order to electrostatically assemble HApNPs into the LbL coating, the pristine HApNPs need to be modified to enhance their surface charges and colloidal stability. Since pure HApNPs only have a poor surface charge and are easily aggregated to precipitate from aqueous solution,<sup>34</sup> several surface techniques have been proposed to address this issue.<sup>35,36</sup> Dopamine chemistry that inspired by the adhesive proteins of mussels for attachment to wet surfaces has been developed widely to modify the solid surface properties.<sup>37,38</sup> Heparin (HEP) is well known to play an important role in regulating adhesion, growth of cells<sup>39,40</sup> and has highly negative charge and steric repulsion effects. In addition, HEP can be used to stabilize rhBMP-2 and improves its activity. In this regard, we propose to develop HEP modified HApNPs using dopamine chemistry to increase their surface charges and colloidal stability.

We first synthesized dopamine grafted heparin (HEP-Dopa) by using EDC/NHS chemistry. The reaction mechanism is roughly as below: firstly, EDC activates carboxyl of HEP to form an unstable reactive *O*-acylisourea ester, then NHS stabilizes

this intermediate by converting it to an amine-reactive NHS ester. This NHS-ester subsequently reacts with nucleophilic free amine group of dopamine to form amide bond. The chemical structure of obtained HEP-Dopa was confirmed by <sup>1</sup>H NMR spectroscopy. The results are shown in Fig. S1.† Compared to the spectrum of HEP, the spectrum of HEP-Dopa indicates a group of new peaks in 6.5–7.0 ppm, which can be ascribed to the characteristic peaks of benzene ring on dopamine. The approximately 34.2% degree of substitution (DS) can be determined by calculating the relative peak intensity ratio between anomeric protons in heparin (5.0–5.6 ppm) and aromatic protons in dopamine (6.5–7.0 ppm).<sup>41</sup>

After mixing HApNPs and HEP-Dopa for 12 h, the heparin moieties can be easily anchored onto HApNPs through the formation of polydopamine coating. The obtained nanoparticles were denoted as HEP-HApNPs. Four pieces of evidence are provided to demonstrate the successful heparin modification.

First, zeta potential results in Fig. 1A show that the surface charge of HApNPs increased significantly from -3 mV to -26 mV after contacting HEP-Dopa solution. Quantitative description of the modified HApNPs size was provided by DLS measurement in Fig. 2B. The heparin modified HApNPs have an average size of about  $180 \pm 20$  nm, while the pristine controls are significantly aggregated due to their weak surface charges, and thus cannot give a nano-scaled particle size (data are not shown here). For dispersion stability test, the samples of pristine HApNPs, heparin physically adsorbed HApNPs and HEP-Dopa modified HApNPs were individually dispersed in PBS solution (Fig. 1C). The colloidal stability was monitored by photography during 24 h incubation. The pristine HApNPs and heparin physically adsorbed HApNPs were observed to be mostly precipitated after 6 h incubation, while HEP-Dopa modified HApNPs display good suspending stability during long time placement. The morphologies of nanoparticles before and after heparin modification were characterized by SEM and TEM in Fig. 1D. The pristine HApNPs were observed to have a fibrous structure and aggregate strongly. After heparin modification, the particles seem to be fat and dispersed very well on the sample stages. The HEP-HApNPs although covered with a heparin coating still have a nano-scaled size. The involved heparin content on HApNPs was calculated as 22  $\mu$ g HEP per 1 mg HEP-HApNPs.

The above results demonstrate that HEP-Dopa molecules can be easily anchored onto the HApNPs surface *via* a dopamine mediated surface coating. The obtained multilayered structure based on the electrostatics interactions.

#### 3.2 Fabrication of hybrid multi-layer coating

In this study, alternate assembly of two oppositely charged species, *i.e.* HEP-Dopa modified HApNPs (HEP-HApNPs) and chitosan (CS), is anticipated to fabricate an inorganic/organic hybrid coating [HEP-HApNPs/CS]<sub>n</sub> ( $n$  represent the bilayer number of the HEP-HApNPs/CS) on the PLGA model surface.

We first performed quartz crystal microbalance measurement (QCM) to demonstrate self-assembly of this multi-layer coating.<sup>42,43</sup>






Fig. 1 Characterization of the pristine HApNPs and heparin modified HApNPs (HEP-HApNPs). (A) Zeta potential of HApNPs and HEP-HApNPs. (B) The size distribution of HEP-HApNPs. (C) Time-dependent colloidal stability of pristine HApNPs, heparin physically adsorbed HApNPs (HEP/HApNPs) and HEP-Dopa modified HApNPs (HEP-HApNPs). (D) TEM (left two) and SEM (right two) images of HApNPs and HEP-HApNPs.

The gold surface of the QCM crystal was initially treated with positively charged polyethyleneimine (PEI). This surface allows the initial layer of HEP-HApNPs to be bound to the sensor through electrostatic interactions. We then sequentially contacted the PEI-coated sensor with solutions of HEP-HApNPs and CS. The QCM measurements in Fig. 2A show decreases in resonant frequency after each contacting step. This observation indicates that multi-layers of HEP-HApNPs and chitosan can be assembled on the basis of electrostatic interactions.

Secondly, the HEP-HApNPs/CS multi-layer coatings with 4, 12 and 20 bilayer number were individually built up on the PLGA film for topography observation. The Fig. 2B reveals that after 4 bilayers deposition, the formed HEP-HApNPs/CS assembly masks most of the original appearance of the substrate. A much more condense and rugged surface was yielded for the coating with 12 bilayers. An unexpected scratch on this coating reveals an obvious morphologic difference

between the coated and uncoated substrate surface. HEP-HApNPs/CS assembled with 20 bilayers has the most rugged topography that is due to plenty of HAp nanoparticles are introduced into this coating. The cross-section images for each coating are shown in the inserts. The evolution of coating thickness alone with the increase of the deposition cycle was quantified. At least five different area for one sample were measured to obtain an averaged value. The coating thicknesses of  $[HEP-HApNPs/CS]_4$ ,  $[HEP-HApNPs/CS]_{12}$  and  $[HEP-HApNPs/CS]_{20}$  were measured to be about  $310 \pm 16$  nm,  $596 \pm 50$  and  $1068 \pm 93$  nm, respectively, which shows a positive correlation to the deposited layer number.

Finally, we analyzed the elemental composition of the coating by XPS measurements. Fig. 2C shows that compared to the bare PLGA substrate, the generated  $[HEP-HApNPs/CS]_{10}$  coating shows new peaks of N 1s, Ca 2p, S 2p, P 2p at 400 eV, 348 eV and 168 eV, 135 eV, respectively. Ca 2p and P 2p peak are




Fig. 2 Characterization of hybrid multi-layer coatings. (A) QCM monitor the layer-by-layer assembly of HEP modified HApNPs (HEP-HApNPs) and chitosan (CS). (B) SEM images of the front view of the bare substrate (PEI aminolysed PLGA film) and the substrates covered by HEP-HApNPs/CS with 4 bilayers, 12 bilayers, and 20 bilayers, respectively. The inserts show the cross-sections of the corresponding samples. (C) XPS spectra of the bare substrate (PEI aminolysed PLGA film) and the [HEP-HApNPs/CS]<sub>10</sub> coating that is formed on the substrate.

assigned to HApNPs. And the signal of S 2p peak can be attributed to the sulfate group on the heparin. The XPS results provide chemical evidence for the successful assembly of HEP-HApNs incorporated coating.

These results demonstrate that a hybrid coating composed of chitosan and heparinized HAp nanoparticles can be easily fabricated using electrostatic interactions as driving force. And also the hybrid coating thickness is finely controlled by the assembly parameters we used for instance the bilayer numbers.

### 3.3 Loading and release of rhBMP-2

We used a coating assembled by 10 bilayers of HEP-HApNPs and CS to evaluate the loading and release behaviors of rhBMP-2. rhBMP-2 was post-loaded into the coating by dropping a certain amount of rhBMP-2 solution onto the as-prepared coating followed by a freeze-drying step. The initial loading amount for rhBMP-2 was about  $2.0 \mu\text{g cm}^{-2}$ . The coating loaded with rhBMP-2 is defined as rhBMP-2@[HEP-HApNPs/CS]<sub>10</sub> and the initial loading percentage is defined as 100% ( $2 \mu\text{g cm}^{-2}$ ).

We further examined the release dynamics of rhBMP-2 from the assembled coating. Bare PLGA substrate loaded with rhBMP-2 at the same level as that on coated substrate was used as control. Fig. 3 shows the release profiles of rhBMP-2 from the two substrates. The control surface exhibits a rapid burst release of over 70% for rhBMP-2 within one day. However, in the presence of hybrid coatings, the release of rhBMP-2 was significantly delayed. Despite of a minor “burst release” occurred at the beginning, a sustained donation of rhBMP-2 was observed over the period of 2 weeks incubation. The initial rapid release is presumably because of some physically adsorbed rhBMP-2 on the outmost surface of coatings. The sustained release of rhBMP-2 in the next stage could be attributed to the incorporated heparin moieties inside the coating that can bind rhBMP-2 *via* their heparin binding domains,<sup>29–32</sup> which is supported by many literatures in that the non-covalent interactions between BMP and heparin have been demonstrated *via* the clusters of positively charged basic amino acids on BMP-2 and specific, spatially grouped, negatively charged sulfate groups on heparin,<sup>44</sup> and this binding is reversible.<sup>45</sup>

After 2 weeks incubation, about 55% of initially loaded rhBMP-2 was observed to be released into the incubation buffer. It is known that a localized and sustained delivery is most favourable for rhBMP-2 when applied *in vivo*.<sup>46</sup> The proposed hybrid coating could be served as an rhBMP-2 reservoir for continuous donation of rhBMP-2 with bioactivity into the defect sites.




Fig. 3 Cumulative release of rhBMP-2 in PBS from bare substrate and substrate with [HEP-HApNPs/CS]<sub>10</sub> coatings, respectively.



### 3.4 Cell viability and morphology on hybrid coatings

A cell-favourable microenvironment should first support cell adhesion and spreading. Cell growth is a prerequisite for further cell growth and development.<sup>47,48</sup>

The viability of the cells cultured on  $[HEP-HApNPs/CS]_{10}$  was evaluated by CCK-8 assay. As shown in Fig. 4A, the cell viability exposed to the coating surface is comparable to that on the bare surface, which indicates that the coating has no obvious cytotoxicity.

The morphology of cells that attached onto the  $[HEP-HApNPs/CS]_{10}$  coating and bare substrate was evaluated by CLSM and SEM, respectively. The upper panel in Fig. 4B shows the SEM observations of cells after 24 h incubation. Cells spread well on the coating surface and exhibited normal filopodia extensions as indicated by the green arrows. A parallel morphology analysis by a nuclei (blue)-cytoskeleton (green) fluorescent staining assay were performed and the CLSM observations are shown in the lower panel in Fig. 4B. The cells all showed elongated and well spread morphology on the coating, and the density of cells were found to be higher on coating surface in comparison to the PLGA bare substrate without any treatment, which could be ascribed to the incorporated biocompatible macromolecules and osteophilic hydroxylapatites in the coating.




Fig. 4 Cell viability and morphology of the C2C12 cells on bare substrate and substrate with  $[HEP-HApNPs/CS]_{10}$ . (A) Cell viability on substrates with or without coating after 3 days incubation, determined by CCK-8 assay. (B) CLSM and SEM observations of the cell morphology adhered on substrates with or without coating for 24 h.

These results indicate that the coating shows excellent cytocompatibility and provide a desirable environment for cell attachment and growth.

### 3.5 *In vitro* cell differentiation on the $[HEP-HApNPs/CS]_{10}$ coating

In this study, rhBMP-2 is loaded into the hybrid coating for induction of osteo-differentiation. In order to evaluate the bio-performance of the incorporated rhBMP-2, we first measured the alkaline phosphatase (ALP) expression of cells that are stimulated by rhBMP-2 loaded hybrid coating *i.e.* rhBMP-2@ $[HEP-HApNPs/CS]_{10}$ . ALP is a standard early marker of osteogenesis in several osteo-progenitor cells. C2C12 myoblast has osteoblastic potential when stimulated by rhBMP-2, therefore




Fig. 5 *In vitro* osteogenic differentiation of cells cultured on bare substrate, substrate with hybrid coating and substrate with rhBMP-2 loaded hybrid coating for 3 days. (A) ALP activity of C2C12 cells. (B) The mRNA expression of osteogenic gene markers ALP, OCN, OPN and RunX2 from BMSC cells by real-time PCR analysis (s.d.,  $n = 3$ , \*\*\* $P < 0.001$ ; \*\* $P < 0.01$ ; \* $P < 0.05$ ).



we use C2C12 to do this study. The cells were seeded on bare substrate, substrate with hybrid coating and substrate with rhBMP-2 loaded coating, respectively. After 3 days incubation, the cells were harvested and lysed for ALP quantification. The result is shown in Fig. 5A. Compared to the cells that cultured in bare substrate and hybrid coating, the cells exposed to rhBMP-2 loaded coating surface show a significant increase in ALP activity, which indicates the rhBMP-2@[HEP-HApNPs/CS]<sub>10</sub> coating contains bioactive rhBMP-2 and thus has excellent osteoinductive ability.

We further investigate the gene expression cascade involved in osteogenesis. Rat BMSC cells were cultured onto the three different substrates individually for three days and the osteogenesis related gene expression that is influenced by the microenvironment of substrate surface are evaluated by real-time PCR analysis. ALP gene is expressed early during the process of osteogenic differentiation, OCN and OPN is expressed later than ALP. RunX2 is a transcription factor that has an effect on the expression of bone-related genes by binding to the promoter of genes. The result in Fig. 5B reveals that compared to the cells cultured on bare substrate, cells that contact the hybrid coating surface slightly up-regulated the four genes that related osteogenesis. This phenomenon could be attributed to the hydroxylapatite component in the hybrid coating. Studies have demonstrated that moderate amount of extracellular calcium ions play an important role in regulating proliferation and osteogenic differentiation of bone mesenchymal stem cells.<sup>49</sup> We thus hypothesize that the electrostatically assembled hybrid coating could also release calcium ions from the incorporated hydroxylapatite nanoparticles through which osteogenesis of the BMSC cells is facilitated. A much more significant gene expression of cells cultured on the rhBMP-2@[HEP-HApNPs/CS]<sub>10</sub> coating is also observed, which is mainly triggered by the sustained released rhBMP-2 from the coating.

All the results demonstrate that the hybrid coating system can incorporate active rhBMP-2 and hydroxylapatite, thus can have the ability to induce cell differentiation towards osteoblasts which facilitates the final osteogenesis.

## 4. Conclusions

The repair of damaged bone tissue requires a favourable biological environment for osteogenesis related cell growth. In this work, we demonstrate that a well designed hybrid coating containing hydroxylapatite nanoparticles, chitosan and rhBMP-2 has been fabricated successfully. Heparin is used to mediate the assembly of hydroxylapatite nanoparticles with chitosan, as well as the subsequent rhBMP-2 loading into the coating. Biological studies indicate our coating system has biocompatibility and can improve the osteo-differentiation especially for rhBMP-2 present coating surface. The results demonstrate that the proposed rhBMP-2 loaded hybrid coating can provide a favourable osteogenic microenvironment and have the potential to improve the *in situ* bone repair due to the superior osteoconductivity as well as osteoinductivity.

## Acknowledgements

This work was supported by National Natural Science Foundation of China (51573047, E0213), Innovation Program of Shanghai Municipal Education Commission (14ZZ060), Shanghai Science and Technology Development Funds (14QA1401000), and the 111 project (B14018).

## Notes and references

- 1 P. S. Lienemann, M. P. Lutolf and M. Ehrbar, *Adv. Drug Delivery Rev.*, 2012, **64**, 1078–1089.
- 2 E. S. Hara, M. Ono, H. T. Pham, W. Sonoyama, S. Kubota, M. Takigawa, T. Matsumoto, M. F. Young, B. R. Olsen and T. Kuboki, *J. Bone Miner. Res.*, 2015, **30**, 1585–1596.
- 3 J. M. Holzwarth and P. X. Ma, *Biomaterials*, 2011, **32**, 9622–9629.
- 4 S. Song, E. J. Kim, C. S. Bahney, T. Miclau, R. Marcucio and S. Roy, *Acta Biomater.*, 2015, **18**, 100–111.
- 5 K. Chen, X. F. Lin, Q. Zhang, J. H. Ni, J. M. Li, J. Xiao, Y. Wang, Y. H. Ye, L. Chen, K. K. Jin and L. Chen, *Acta Biomater.*, 2015, **19**, 46–55.
- 6 F. Goncalves, R. Bentini, M. C. Burrows, A. C. O. Carreira, P. M. Kossuge, M. C. Sogayar and L. H. Catalani, *Materials*, 2015, **8**, 408–423.
- 7 A. Lopez-Noriega, E. Ruiz-Hernandez, E. Quinlan, G. Storm, W. E. Hennink and F. J. O'Brien, *J. Controlled Release*, 2014, **187**, 158–166.
- 8 P. B. Zhang, H. T. Wu, H. Wu, Z. W. Lu, C. Deng, Z. K. Hong, X. B. Jing and X. S. Chen, *Biomacromolecules*, 2011, **12**, 2667–2680.
- 9 J. Xie, C. Peng, Q. H. Zhao, X. L. Wang, H. H. Yuan, L. L. Yang, K. Li, X. X. Lou and Y. Z. Zhang, *Acta Biomater.*, 2016, **29**, 365–379.
- 10 T. Jiang, S. P. Nukavarapu, M. Deng, E. Jabbarzadeh, M. D. Kofron, S. B. Doty, W. I. Abdel-Fattah and C. T. Laurencin, *Acta Biomater.*, 2010, **6**, 3457–3470.
- 11 Y. C. Wu, S. Y. Shaw, H. R. Lin, T. M. Lee and C. Y. Yang, *Biomaterials*, 2006, **27**, 896–904.
- 12 K. X. Zhang, S. M. He, S. F. Yan, G. F. Li, D. Q. Zhang, L. Cui and J. B. Yin, *J. Mater. Chem. B*, 2016, **4**, 2628–2645.
- 13 Z. S. Patel, S. Young, Y. Tabata, J. A. Jansen, M. E. K. Wong and A. G. Mikos, *Bone*, 2008, **43**, 931–940.
- 14 C. T. Wu, W. Fan, M. Gelinsky, Y. Xiao, P. Simon, R. Schulze, T. Doert, Y. X. Luo and G. Cuniberti, *Acta Biomater.*, 2011, **7**, 1797–1806.
- 15 D. Gopi, E. Shinyjoy, A. Karthika, S. Nithiya, L. Kavitha, D. Rajeswari and T. T. Tang, *RSC Adv.*, 2015, **5**, 36766–36778.
- 16 R. Rajesh and Y. D. Ravichandran, *RSC Adv.*, 2015, **5**, 41135–41143.
- 17 S. F. Zhang, C. Kucharski, M. R. Doschak, W. Sebald and H. Uludag, *Biomaterials*, 2010, **31**, 952–963.
- 18 S. F. Zhang, M. R. Doschak and H. Uludag, *Biomaterials*, 2009, **30**, 5143–5155.
- 19 C. M. Xie, X. Lu, K. F. Wang, F. Z. Meng, O. Jiang, H. P. Zhang, W. Zhi and L. M. Fang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 8580–8589.

20 S. E. Bae, J. Choi, Y. K. Joung, K. Park and D. K. Han, *J. Controlled Release*, 2012, **160**, 676–684.

21 C. Y. Chien and W. B. Tsai, *ACS Appl. Mater. Interfaces*, 2013, **5**, 6975–6983.

22 Y. H. Jiao, Y. Li, S. Wang, K. Zhang, Y. G. Jia and Y. Fu, *Langmuir*, 2010, **26**, 8270–8273.

23 J. Hong, N. J. Shah, A. C. Drake, P. C. DeMuth, J. B. Lee, J. Z. Chen and P. T. Hammond, *ACS Nano*, 2012, **6**, 81–88.

24 M. L. Macdonald, R. E. Samuel, N. J. Shah, R. F. Padera, Y. M. Beben and P. T. Hammond, *Biomaterials*, 2011, **32**, 1446–1453.

25 N. J. Shah, M. L. Macdonald, Y. M. Beben, R. F. Padera, R. E. Samuel and P. T. Hammond, *Biomaterials*, 2011, **32**, 6183–6193.

26 S. G. Caridade, C. Monge, J. Almodovar, R. Guillot, J. Lavaud, V. Josserand, J. L. Coll, J. F. Mano and C. Picart, *Acta Biomater.*, 2015, **15**, 139–149.

27 N. J. Shah, J. Hong, M. N. Hyder and P. T. Hammond, *Adv. Mater.*, 2012, **24**, 1445–1450.

28 X. Qu, F. He, H. Q. Tan, Y. M. Yu, A. Axrap, M. Wang, K. Dai, Z. Zhang, F. Yang, S. G. Wang, J. Kohn and C. S. Liu, *J. Mater. Chem. B*, 2016, **4**, 4901–4912.

29 F. Blanquaert, D. Barritault and J. P. Caruelle, *J. Biomed. Mater. Res.*, 1999, **44**, 63–72.

30 H. Lin, Y. Zhao, W. Sun, B. Chen, J. Zhang, W. Zhao, Z. Xiao and J. Dai, *Biomaterials*, 2008, **29**, 1189–1197.

31 T. Hu, S. A. Abbah, M. Wang, S. Y. Toh, R. W. M. Lam, M. Naidu, G. Bhakta, S. M. Cool, K. Bhakoo, J. Li, J. C. H. Goh and H. K. Wong, *Spine*, 2015, **40**, 613–621.

32 C. Ma, Y. Jing, H. Sun and X. Liu, *Adv. Healthcare Mater.*, 2015, **4**, 2699–2708.

33 T. Takada, T. Katagiri, M. Ifuku, N. Morimura, M. Kobayashi, K. Hasegawa, A. Ogamo and R. Kamijo, *J. Biol. Chem.*, 2003, **278**, 43229–43235.

34 M. N. Salimi, R. H. Bridson, L. M. Grover and G. A. Leeke, *Powder Technol.*, 2012, **218**, 109–118.

35 W. M. Chirdon, W. J. O'Brien and R. E. Robertson, *J. Biomed. Mater. Res., Part B*, 2003, **66**, 532–538.

36 T. G. Kim, S.-H. Park, H. J. Chung, D.-Y. Yang and T. G. Park, *J. Mater. Chem.*, 2010, **20**, 8927.

37 H. Lee, S. M. Dellatore, W. M. Miller and P. B. Messersmith, *Science*, 2007, **318**, 426–430.

38 J. H. Cho, K. Shanmuganathan and C. J. Ellison, *ACS Appl. Mater. Interfaces*, 2013, **5**, 3794–3802.

39 Y. Yang, P. K. Qi, F. Wen, X. Y. Li, Q. Xia, M. F. Maitz, Z. L. Yang, R. Shen, Q. F. Tu and N. Huang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 14608–14620.

40 L. Ma, H. Qin, C. Cheng, Y. Xia, C. He, C. X. Nie, L. R. Wang and C. S. Zhao, *J. Mater. Chem. B*, 2014, **2**, 363–375.

41 T. G. Kim, H. Lee, Y. Jang and T. G. Park, *Biomacromolecules*, 2009, **10**, 1532–1539.

42 N. Aggarwal, N. Altgarde, S. Svedhem, K. Zhang, S. Fischer and T. Groth, *Langmuir*, 2013, **29**, 13853–13864.

43 N. Aggarwal and T. Groth, *J. Biomed. Mater. Res., Part A*, 2014, **102**, 4224–4233.

44 I. Capila and R. J. Linhardt, *Angew. Chem., Int. Ed.*, 2002, **41**, 391–412.

45 M. H. Hettiaratchi, T. Miller, J. S. Temenoff, R. E. Guldberg and T. C. McDevitt, *Biomaterials*, 2014, **35**, 7228–7238.

46 R. H. Li and J. M. Wozney, *Trends Biotechnol.*, 2001, **19**, 255–265.

47 T. Hoshiba, N. Kawazoe, T. Tateishi and G. P. Chen, *J. Biol. Chem.*, 2009, **284**, 31164–31173.

48 H. Ceylan, A. B. Tekinay and M. O. Guler, *Biomaterials*, 2011, **32**, 8797–8805.

49 R. Mentaverri, S. Yano, N. Chattopadhyay, L. Petit, O. Kifor, S. Kamel, E. F. Terwilliger, M. Brazier and E. M. Brown, *FASEB J.*, 2006, **20**, 2562–2564.

